



**EVALUATION OF THREE-DOSE FOSFOMYCIN
TROMETHAMINE IN THE TREATMENT OF PATIENTS WITH
URINARY TRACT INFECTIONS: AN UNCONTROLLED, OPEN-
LABEL, MULTICENTER STUDY**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004157
Article Type:	Research
Date Submitted by the Author:	01-Oct-2013
Complete List of Authors:	Qiao, Lu-Dong; Beijing Tongren Hospital Capital Medical University, Urology Zheng, Bo; Peking University First Hospital, Institute of Clinical Pharmacology Chen, Shan; Beijing Tongren Hospital Capital Medical University, Urology Yang, Yong; Beijing Cancer Hospital, Urology Zhang, Kai; Peking University First Hospital, Urology Guo, Hong-Feng; Peking University Shougang Hospital (Jieping Wu Urology Center), Urology Yang, Bo; Peking University People's Hospital, Urology Niu, Yuan-Jie; Second Affiliated Hospital of Tianjin Medical University, Urology Wang, Yi; First Affiliated Hospital of Tianjin Medical University, Urology Shi, Ben-Kang; Qilu Hospital of Shandong University, Urology Yang, Wei-Min; Hubei Tongji Hospital, Urology Zhao, Xiao-Kun; Hunan Xiangya Second Hospital, Urology Gao, Xiao-Feng; Shanghai Changhai Hospital, Urology Chen, Ming; Zhongda Hospital affiliated to Southeast University, Urology
Primary Subject Heading:	Urology
Secondary Subject Heading:	Urology
Keywords:	UROLOGY, Urinary tract infections < UROLOGY, Adult urology < UROLOGY

SCHOLARONE™
Manuscripts

**EVALUATION OF THREE-DOSE FOSFOMYCIN TROMETHAMINE IN THE
TREATMENT OF PATIENTS WITH URINARY TRACT INFECTIONS: AN
UNCONTROLLED, OPEN-LABEL, MULTICENTER STUDY**

**Lu-Dong Qiao^{1#}; Bo Zheng^{2#}; Shan Chen^{1*}; Yong Yang³; Kai Zhang⁴; Hong-Feng Guo⁵;
Bo Yang⁶; Yuan-Jie Niu⁷; Yi Wang⁸; Ben-Kang Shi⁹; Wei-Min Yang¹⁰; Xiao-Kun Zhao¹¹;
Xiao-Feng Gao¹²; Ming Chen¹³**

¹Department of Urology. Beijing Tongren Hospital Capital Medical University, Beijing, P. R. China

²Institute of Clinical Pharmacology. Peking University First Hospital, Beijing, P. R. China

³Department of Urology. Beijing Cancer Hospital, Beijing, P. R. China

⁴Department of Urology. Peking University First Hospital, Beijing, P. R. China

⁵Department of Urology. Peking University Shougang Hospital (Jieping Wu Urology Center), Beijing, P. R. China

⁶Department of Urology. Peking University People's Hospital, Beijing, P. R. China

⁷Department of Urology. Second Affiliated Hospital of Tianjin Medical University, Tianjin, P. R. China

⁸Department of Urology. First Affiliated Hospital of China Medical University, Shenyang, P. R. China

⁹Department of Urology. Qilu Hospital of Shandong University, Jinan, P. R. China

¹⁰Department of Urology. Wuhan Hubei Tongji Hospital, Wuhan, P. R. China

¹¹Department of Urology. Hunan Province Xiangya Second Hospital, Changsha, P. R. China

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

¹²Department of Urology. Shanghai Changhai Hospital, Shanghai, P. R. China

¹³Department of Urology. Zhongda Hospital Southeast University, Nanjing, P. R. China

*Correspondence to: Shan Chen, Department of Urology, Beijing Tongren Hospital Capital

Medical University; Address: No. 1, Dong Jiao Min Xiang, 100730 Beijing, P. R. China;

E-mail: shanchentr001@163.com

#Both authors contributed equally to the study and share first authorship.

Keywords: fosfomycin tromethamine; urinary tract infection; efficacy; safety; China

Word count: 2154

Abstract:

Objective: To evaluate the clinical and microbiological efficacy and safety of three doses of 3 g fosfomycin tromethamine administered orally to treat urinary tract infections.

Design and participants: This prospective, uncontrolled, open-label study was conducted in 12 medical centers in China, between January and December 2011. According to the diagnosis criteria of Chinese Guidelines on Urological Infections, patients (18–70 years old) with acute uncomplicated cystitis, recurrent urinary tract infection or complicated urinary tract infection received three doses of 3 g fosfomycin tromethamine orally, at days 1, 3 and 5.

Primary and secondary outcome measures: Efficacy endpoints (clinical efficacy, microbiological efficacy and overall efficacy) was evaluated for day 15. Clinical symptoms, physical signs, urinalysis, liver and kidney function, patient records and evaluation of adverse events (AEs) and serious adverse events (SAEs) up to day 15 were evaluated for analysis of safety.

Results: 361 patients were included in the full analysis set (FAS), 356 in the safety analysis set (SS) and 335 in the per-protocol set (PPS). In the PPS, the clinical efficacy rates at day 15 for acute uncomplicated cystitis, recurrent urinary tract infection and complicated urinary tract infection were 94.71% (179/189), 77.22% (61/79), and 62.69% (42/67), respectively. Microbiological efficacy rates (day 15) were 97.65% (83/85), 94.44% (34/36) and 83.87% (26/31), respectively. The overall efficacy rates (day 15) were 95.29% (81/85), 77.78% (28/36) and 64.52% (20/31), respectively. 20/356 (5.6%) patients reported drug-related AEs, the most common being diarrhea. No serious drug-related AEs were reported.

Conclusions: This fosfomycin tromethamine dosing regimen showed clinical and

1
2
3
4 microbiological efficacy with some AEs and good tolerability in patients with acute
5
6 uncomplicated cystitis, recurrent urinary tract infection and complicated urinary tract
7
8 infection.
9

10 11 12 13 14 **Article summary:**

15 16 **Article focus:**

- 17 • Urinary tract infections (UTIs) are a common clinical infectious disease.
- 18 • Increasing drug resistance against other oral antibiotics makes fosfomycin
- 19 tromethamine a valuable alternative in the treatment of UTIs.
- 20 • The aim of this study was to evaluate the clinical and microbiological efficacy and
- 21 safety of fosfomycin tromethamine in UTI patients from China.
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30

31 32 **Key messages:**

- 33 • Overall, oral administration of three doses of 3 g fosfomycin tromethamine on days 1,
- 34 3 and 5 showed good clinical and microbiological efficacy in the treatment of acute
- 35 uncomplicated cystitis, recurrent UTI and complicated UTI.
- 36 • The dosage regimen used in this study was associated with a clinically acceptable
- 37 safety profile, the most frequent adverse event being mild diarrhea, in-line with
- 38 previous studies. No abnormal laboratory results were recorded.
- 39 • Three single 3 g doses of fosfomycin tromethamine taken orally, every other day,
- 40 were effective and well tolerated. We believe that this dosage regimen can be adopted
- 41 to treat UTIs in clinical practice.
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55

56 57 **Strengths and limitations of this study:**

- To the best of our knowledge, this is the first multicenter study to evaluate fosfomycin tromethamine in the treatment of UTIs in China.
- We used the same dosage regimen for the different types of UTI. The dosage may not be sufficient for the complicated UTI, but may exceed the required dose for acute uncomplicated cystitis. Further studies using different dosing regimens for the different types of infection are needed.

For peer review only

INTRODUCTION

Urinary tract infections (UTIs) are a common clinical infectious disease. Every year, there are more than 7 million outpatients and about one million patients are hospitalized due to UTIs.[1]

Death caused by septic shock due to UTIs ranks third among all lethal infections.[2] In China, UTIs account for 9.39%–50% of all nosocomial infections.[3,4]

In recent years, many resistant strains have emerged as a consequence of the use of broad-spectrum cephalosporins. In particular, strains producing extended-spectrum beta lactamase (ESBL) have created a considerable obstacle in the clinical treatment of UTIs. The fosfomycin derivative fosfomycin tromethamine, a broad-spectrum bactericidal antibiotic inhibiting the synthesis of the bacterial cell wall, has been able to maintain resistance rates amongst *Escherichia coli* as low as 1% worldwide.[5] Available evidence suggests that, even for ESBL-producing *E. coli*, the resistance rate to fosfomycin can be maintained at 3.4%–16.1%.[6,7] The increasing difficulties associated with the increasing drug resistance against other oral antibiotics makes fosfomycin even more valuable in the treatment of UTIs. In order to obtain a deeper understanding of its therapeutic effect in domestic patients, we evaluated the clinical and microbiological efficacy and safety in UTI patients from 12 research centers in China.

METHODS

Study design and participants

1
2
3
4 This was a prospective, uncontrolled, open-label and multicenter study approved by the ethics
5
6 committee of the Beijing Tongren Hospital. Eligible patients were between 18 and 70 years of
7
8 age and had sought medical help for acute uncomplicated cystitis (AUC), recurrent UTI or
9
10 complicated UTI[8] in a urology department of one of 12 medical centers in China (see
11
12 appendix) from January 2011 to December 2011. All study participants provided informed
13
14 consent.
15
16

17
18 The main exclusion criteria were: a history of allergy to fosfomycin; susceptibility results
19
20 showing resistance to the test drug; fever; grade 3 or 4 cardiac insufficiency; pregnant or
21
22 lactating women, or women of childbearing age with a positive urine pregnancy test; acute
23
24 pyelonephritis or acute bout of chronic pyelonephritis; previously diagnosed renal failure;
25
26 liver disease, with ALT or AST greater than 2 times the upper limit of normal range; white
27
28 blood cell count less than 2.0×10^9 /L; receipt of other anti-infective drugs within 72 hours
29
30 before enrollment; patients in the late stages of malignant tumors; long-term use of hormones
31
32 or immunosuppressants; a history of epilepsy or central nervous system disorders; severe
33
34 diarrhea; participation in another clinical trial within 3 months prior to enrollment.
35
36
37
38
39
40
41
42
43

44 **Test drug and dosing regimen**

45
46 The test drug was fosfomycin tromethamine powder (3 g fosfomycin per bottle), produced by
47
48 Shanxi C&Y Pharmaceutical Co., Ltd., batch number-20100626.
49

50
51 Treatment duration was 5 days: on the first day (day 1), a dose of 3 g fosfomycin
52
53 tromethamine powder was dissolved with an appropriate amount of water and taken on an
54
55 empty stomach before dinner; two further doses of 3 g fosfomycin tromethamine powder
56
57
58
59
60

1
2
3
4 were taken orally in the evening of days 3 and 5, before bedtime.
5
6
7

8 9 **Clinical observations**

10 Infection signs and symptoms, including frequent, urgent, painful, and difficult urination,
11 were noted on days 1, 8, and 15.
12
13

14 Blood count, including white blood cells, red blood cells, platelets, neutrophils, lymphocytes,
15 eosinophils and hemoglobin, was performed on days 1 and 8. Patients with abnormal levels
16 on day 8 were reexamined on day 15.
17
18

19 Urinalysis, including urine proteins, red and white blood cells, was performed on days 1, 8,
20 and 15.
21
22

23 Blood biochemistry, including liver functions (ALT, AST, γ -GT, TBIL, DBIL) and renal
24 functions (BUN, Cr), was assessed on days 1 and 8. Patients with abnormal levels on day 8
25 were reexamined on day 15.
26
27

28 Bacterial cultures were obtained for days 1, 8, and 15, using aseptic techniques to collect
29 midstream specimens of urine.
30
31

32 33 34 35 36 37 38 39 40 41 42 43 **Evaluation of efficacy and safety**

44 Clinical efficacy, microbiological efficacy, overall efficacy and safety were evaluated on day
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Evaluation of clinical efficacy

The clinical effect on the UTIs of participants was described using the following 3 grades:

cured (symptoms and signs disappeared completely), improved (symptoms and signs

1
2
3
4 improved markedly) and ineffective (symptoms and signs worsened or had no significant
5
6 improvement). Both “cured” and “improved” were considered “effective” results and were
7
8 used to calculate the clinical efficacy rate.
9

10 Evaluation of microbiological efficacy

11
12 The microbiological efficacy for each patient with positive urine culture was evaluated from
13
14 day 1. We assessed the microbiological effect using the following 5 grades: cleared (no
15
16 pathogenic bacteria in the urine were present on days 8 and 15), partially cleared (at least one
17
18 of several pathogenic bacteria, but not all, were cleared by days 8 and 15), not cleared
19
20 (pathogenic bacteria were still present on days 8 and 15), replacement (a new pathogenic
21
22 bacteria was detected on days 8 and 15, but the patient had no clinical symptoms and no
23
24 treatment was necessary) and re-infection (a new pathogenic bacteria was detected on days 8
25
26 and 15; the patient had symptoms and treatment was necessary). Microbiological test results
27
28 showing “cleared”, “partially cleared”, “replacement” or “re-infection” were considered
29
30 “effective” results and were used to calculate the microbiological efficacy rate.
31
32
33
34
35
36
37
38

39 Evaluation of overall efficacy

40
41 Overall efficacy was assessed on patients for whom both clinical and microbiological
42
43 efficacy data were available by day 15. Four grades were used: excellent (all assessments
44
45 [clinical symptoms, physical signs, laboratory tests and bacteriological examinations] had
46
47 returned to normal by day 15), good (the condition improved markedly, but one of the
48
49 described assessments remained out of the normal range), fair (some improvement was
50
51 observed after treatment, but two of the described assessments failed to return to normal) and
52
53 poor (no significant improvement was observed or the assessments worsened). Cases graded
54
55
56
57
58
59
60

1
2
3
4 as “excellent” or “good” were considered “effective” results and were used to calculate the
5
6 overall efficacy rate.
7

8 9 Evaluation of safety

10
11 Clinical symptoms, physical signs, urinalysis, liver and kidney function, all patient records
12
13 and evaluation of adverse events (AEs) and serious adverse events (SAEs) were considered
14
15 for the safety evaluation. According to their severity, AEs were categorized by patients as
16
17 follows: “no discomfort”, “mild discomfort”, “moderate discomfort” and “severe discomfort”.
18
19 The association between AEs and the study drug was assessed by the physician as “definitely
20
21 related”, “probably related”, “possibly related”, “possibly not related” and “definitely not
22
23 related”.
24
25
26
27
28
29
30

31 32 **Statistical methods**

33
34 The data management software EpiData was used for data entry (Lauritsen JM. EpiData Data
35
36 Entry, Odense Denmark, EpiData Association, 2000-2008. Available from:
37
38 <http://www.epidata.dk>). Each case report form was completed by two persons and entry
39
40 results were compared using SAS software (Version 9.2). The verified data were then entered
41
42 into a database that was considered as final and correct. For efficacy evaluation, the efficacy
43
44 rates were calculated as a ratio between the “effective” cases and the total number of patients.
45
46 For safety analyses, the number of patients with AEs, drug related AEs, and the incidence of
47
48 AEs were calculated.
49
50
51
52

53
54 The populations included in the analyses were handled as follows: all selected patients who
55
56 received the study drug were included in the full analysis set (FAS). The per-protocol set
57
58
59
60

1
2
3
4 (PPS) included the patients from FAS who did not meet the following conditions: (1)
5
6 inclusion criteria or exclusion criteria violation; (2) use of prohibited concomitant
7
8 medications; (3) administration of the study drug less than 3 times; (4) failure to undergo the
9
10 examinations required to determine the clinical effect; (5) poor compliance with the study
11
12 drug. The PPS population was considered the primary analysis population. All patients who
13
14 received at least one dose of the study drug and had data available for all safety endpoints
15
16 were included in the safety analysis set (SAS).
17
18
19
20
21
22
23

24 **RESULTS**

25 **Baseline demographics**

26
27
28
29
30
31 361 patients enrolled at 12 centers were included in the FAS. 5 patients did not take the test
32
33 drugs and were excluded, resulting in 356 patients being included in the SAS. 21 patients
34
35 were further excluded due to failure to undergo the examinations required to determine the
36
37 clinical effect, resulting in 335 patients being included in the PPS. Demographic data and
38
39 infection types for FAS and PPS are shown in Table 1.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic characteristics of patients at enrollment

Variables	Parameter	FAS		PPS	
		n	%	n	%
Gender	male	114	31.58	105	29.08
	female	247	68.42	230	63.71
Age (years)		49.63 ± 16.64		49.91 ± 16.61	
Height (cm)		163.55 ± 7.12		163.47 ± 7.05	
Weight (kg)		61.36 ± 10.2		61.44 ± 9.81	
Antibiotics*		45	12.53	43	12.84
Hypertension		65	18.01	62	18.51
Diabetes		25	6.93	24	7.16
	AUC	204	56.51	189	56.42
UTI diagnosis**	recurrent UTI	87	24.38	79	23.58
	complicated UTI	69	19.11	67	20.00

Footnote: *use of antibiotics <72 h prior to enrollment; **for 1 patient, the diagnosis was uncertain; FAS = full analysis set; PPS = per-protocol set; AUC = acute uncomplicated cystitis; UTI = urinary tract infection; n = number of patients.

Clinical efficacy

On day 15, the fosfomycin tromethamine treatment showed clinical efficacy in 282/335 patients. Of these, the symptoms and signs of 228/335 (65.07%) patients were graded as “cured”. Clinical efficacy rates for patients of different gender, age, or with different infection

types are shown in Table 2.

Table 2. Clinical efficacy at day 15 (per-protocol set)

Variables	n	Effective	Ineffective	Efficacy	
		n	n	rate (%)	
Gender	Male	105	77	28	73.33
	Female	230	205	25	89.13
Age	<50 years	154	137	17	88.96
	≥50 years	181	145	36	80.11
	AUC	189	179	10	94.71
Diagnosis	Recurrent UTI	79	61	18	77.22
	Complicated UTI	67	42	25	62.69

Footnote: AUC = acute uncomplicated cystitis; UTI = urinary tract infection;

n = number of patients.

Microbiological efficacy

198/356 patients had positive cultures from urine samples collected on day 1, before receiving the first dose of treatment. Microbiological efficacy was determined for 152 patients (46/198 patients did not have urine cultures at follow-up visits). 127/152 (83.55%) patients had a microbiological efficacy grade of “cleared”, 0/152 patients were graded as “partially cleared”, 9/152 (5.92%) patients were graded as “not cleared”, 15/152 (9.87%) patients as “replacement” and 1/152 (0.66%) patients as “re-infected”. The percentage of patients showing effective treatment in terms of microbiological results was 94.08%.

Microbiology efficacy by infection type is shown in Table 3.

Table 3. Microbiology efficacy by infection type (152 cases)

Diagnosis	n	Effective	Ineffective	Efficacy rate
		n	n	(%)
AUC	85	83	2	97.65
Recurrent UTI	36	34	2	94.44
Complicated UTI	31	26	5	83.87

Footnote: AUC = acute uncomplicated cystitis;

UTI = urinary tract infection; n = number of patients.

Overall efficacy

Overall efficacy was assessed for the 152 patients with available microbiological test results.

106/152 (69.74%) patients were considered to be “excellent”, 23/152 (15.13%) patients were “good”, 14/152 (9.21%) patients were “fair” and 9/152 (5.92%) patients were “poor”. Overall efficacy rate by infection type is shown in Table 4.

Table 4. Overall efficacy by infection type (152 cases)

Diagnosis	n	Effective	Ineffective	Efficacy rate
		n	n	(%)
AUC	85	81	4	95.29
Recurrent UTI	36	28	8	77.78
Complicated UTI	31	20	11	64.52

Footnote: AUC = acute uncomplicated cystitis;

1
2
3
4 UTI = urinary tract infection; n = number of patients.
5
6
7

8 9 **Safety evaluation**

10
11 AEs were reported in 20/356 (5.6%) patients; the most frequently reported event was diarrhea
12
13 (18/356 [5.06%]). 14 patients had mild diarrhea, and 4 had moderate diarrhea. One patient
14
15 (0.28%) reported mild fatigue and one patient reported mild backache. One patient
16
17 discontinued the trial due to moderate diarrhea. All other AEs resolved without further
18
19 treatment. No patients showed abnormal laboratory test results.
20
21
22
23
24
25

26 27 **DISCUSSION**

28
29
30
31 Fosfomycin tromethamine has been used in clinical practice for many years in Europe, but
32
33 rarely used in China until recently. To the best of our knowledge, this is the first multicenter
34
35 study to evaluate fosfomycin tromethamine in the treatment of UTIs in China. It has been
36
37 previously observed that one dose of 3 g fosfomycin tromethamine taken orally reaches a
38
39 peak concentration in the urine of 1,053–4,415 mg/L and the fosfomycin concentration in
40
41 urine is maintained at levels greater than 128 mg/L for 24–48 hours, which is sufficient to
42
43 suppress a variety of pathogenic bacteria in the urinary tract.[9] In the current study, patients
44
45 received 3 doses of 3 g fosfomycin tromethamine every other day.
46
47
48

49
50
51 With bacterial resistance rising worldwide, the European Urology Association adjusted their
52
53 recommendations for the treatment of AUC in the Guidelines on Urological Infections
54
55 2010.[10] The initial recommended first-line drugs, such as sulfamethoxazole trimethoprim
56
57
58
59
60

1
2
3
4 (SMZ TMP) and fluoroquinolones, are now recommended as second choice drugs, while
5
6 fosfomycin tromethamine is now recommended as the preferred treatment. Stein[11] made a
7
8 comprehensive analysis of published randomized controlled clinical studies (Medline
9
10 1970-1997) and unpublished studies submitted to the Food and Drug Administration on
11
12 fosfomycin tromethamine treatment of uncomplicated UTI. The results suggested that a
13
14 single dose of 3 g fosfomycin tromethamine, taken orally, is superior in terms of compliance
15
16 and efficacy to conventional therapy (SMZ TMP, nitrofurantoin and fluoroquinolones)
17
18 administered over 3 to 7 days to treat uncomplicated UTIs. In line with this, we obtained
19
20 clinical, microbiological, and overall efficacy rates of 94.71%, 97.65%, and 95.29%,
21
22 respectively, for the treatment of AUC using fosfomycin tromethamine; and 77.22%, 94.44%
23
24 and 77.78%, respectively, for recurrent UTI.
25
26
27
28
29
30

31 Complicated UTIs are associated with conditions such as a structural or functional
32
33 abnormality of the genitourinary tract, or the presence of an underlying disease that interferes
34
35 with host defense mechanisms, increasing the risks of acquiring infection or of failing therapy.
36
37 Complicated UTI is caused by a broader spectrum of pathogenic bacteria, and is associated
38
39 with a higher level of drug resistance, than uncomplicated UTI. Domestic research has shown
40
41 that the isolation rate for ESBL-producing *E. coli* is 44% in complicated UTI, with
42
43 susceptibility data showing that ESBL-producing strains have significantly higher resistance
44
45 against commonly used antibiotics than the non-ESBL-producing strains.[12,13] With a
46
47 growing proportion of ESBL-producing strains identified in UTIs, the resistance rate of *E.*
48
49 *coli* to commonly used second and third generation cephalosporins has increased to more
50
51 than 45%.[14] This creates considerable obstacles for effective antimicrobial use in clinical
52
53
54
55
56
57
58
59
60

1
2
3
4 practice. As a direct result, an increasing amount of carbapenem has been used in the
5
6 empirical treatment of complicated UTI, which has led to an increase in bacterial resistance,
7
8 an imbalance of commensal flora, and increased risk of fungal infection.[15] Previous
9
10 single-center studies have shown good results achieved with fosfomycin in the treatment of
11
12 UTIs caused by ESBL-producing bacteria.[16] In line with this, the current study showed
13
14 clinical, microbial and overall efficacy rates of 62.69%, 83.87% and 64.52%, respectively, in
15
16 the treatment of complicated UTI.
17
18

19
20 We observed a low frequency of AEs in the current study. Our findings are in line with an
21
22 overview of safety and tolerability results from 12 open and double-blind comparative
23
24 studies,[17] in which 891 female patients received a single 3 g dose of fosfomycin
25
26 tromethamine. In that study, AEs were reported for 6.1% of the patients, with the most
27
28 frequent complaints being gastro-intestinal complaints.
29
30

31
32 One limitation of this study results from the same dosage regimen (3 doses, of 3 g each, of
33
34 fosfomycin tromethamine taken orally) used for the different types of UTI. The dosage may
35
36 not be sufficient for the complicated UTI, but may exceed the required dosage for simple
37
38 AUC. Therefore, further in-depth studies will be needed with different treatment regimens for
39
40 the different types of infection.
41
42
43
44
45
46
47

48 49 **CONCLUSIONS**

50
51
52
53
54 The current study suggests that three single 3 g doses of fosfomycin tromethamine taken
55
56 orally, every other day, are effective and well tolerated, with a clinically acceptable safety
57
58
59
60

1
2
3
4 profile in the treatment of AUC, recurrent UTI or complicated UTI. We believe that this
5
6 dosage regimen can be adopted to treat UTIs in clinical practice.
7
8
9

10
11 **Acknowledgements:** Authors would like to thank all study participants and the general
12
13 practitioners, study nurses and personnel who contributed to this study. Authors wish to
14
15 acknowledge the support provided by Linyu Li and Jinghan Zhang. Authors also thank
16
17 Juliette Gray and Adriana Rusu (XPE Pharma & Science) for editorial support.
18
19

20
21 **Contributors:** The work presented here was carried out in collaboration between all authors.
22
23 Shan Chen, Lu-dong Qiao and Bo Zheng designed research and defined the research theme;
24
25 Lu-dong Qiao, YongYang, Kai Zhang, Hong-feng Guo, Bo Yang, Yuan-jie Niu, Yi Wang,
26
27 Ben-kang Shi, Wei-min Yang, Xiao-kun Zhao, Xiao-feng Gao, Ming Chen performed the
28
29 research; Shan Chen and Lu-dong Qiao analyzed data, interpreted the results. All authors
30
31 attended the written of the paper and have read and approved the manuscript.
32
33
34

35
36 **Funding:** This research received no specific grant from any funding agency in the public,
37
38 commercial or not-for-profit sectors.
39

40
41 **Competing interests:** None.
42

43
44 **Data sharing statement:** No additional data are available.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference list

1. Foxman B: Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. *Am J Med* 2002;**113**:5S–13S.
2. Pinner RW, Teutsch SM, Simonsen L, et al: Trends in infectious disease mortality in the United States. *JAMA* 1996;**275**:189–93.
3. Wang JQ, Wu XP, Li YJ, et al: Nosocomial infection point-prevalence survey in three consecutive years. *Chin J Infect Control* 2006;**01**:19–34.
4. Wang JX, Zhu XL, Yang LY: A nosocomial infection point-prevalence survey: results and analysis. *Chinese Journal of Nosocomiology* 2005;**10**:1119–20.
5. Schito GC: Why fosfomycin trometamol as first line therapy for uncomplicated UTI? *Int J Antimicrob Agents* 2003;**22**:79–83.
6. Qi J, Cheng X: Results analysis of ESBLs-producing *E. coli* in vitro susceptibility to fosfomycin. *China Tropical Medicine* 2010;**10**:734–5.
7. Da PN, Rong M, Yong EL: In vitro antimicrobial activity of fosfomycin against gram-negative bacilli. *Dalian Medical University* 2010;**32**:577–9.
8. Na YQ, Sun G. Guidelines for diagnosis and treatment of urological diseases in China, 2009. Beijing: People's Health Publishing House 2009:643–4.
9. Patel SS, Balfour JA, Bryson HM: Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. *Drugs* 1997;**53**:637–56.
10. Grabe M, Bjerklund-Johansen TE, Botto H, et al: European Association of Urology,

- Guidelines on Urological Infections, 2010. Available at: <http://www.uroweb.org/>
11. Stein GE: Single-dose treatment of acute cystitis with fosfomycin tromethamine. *Ann Pharmacother* 1998;**32**:215–9.
 12. Qiao LD, Chen S: Analysis of risk factors about ESBLs-producing *E. coli* urinary tract infection. *J Hosp Infect* 2011;**21**:247–9.
 13. Kong HS, Wang BG: Comparative study of antibiotic resistance in clinical isolates of *Klebsiella pneumoniae* and *Escherichia coli* producing extended-spectrum beta lactamases. *J Lab Med* 2000;**23**:23–5.
 14. Gao L, Xiao YH: 2006 – 2007 Mohnarlin report: Bacterial distribution and resistance in urinary tract infections. *Chinese Journal of Antibiotics* 2008;**33**:586–91.
 15. Chen H, Liu Y: Relationship between antimicrobial treatment and imbalance of intestinal flora in the elders. *Practical Clinical Medicine*, 2007;**9**:34–6.
 16. Pullukcu H, Tasbakan M, Sipahi OR, et al: Fosfomycin in the treatment of extended spectrum beta-lactamase-producing *Escherichia coli*-related lower urinary tract infections. *Int J Antimicrob Agents* 2007;**29**:62–5.
 17. Naber KG: Fosfomycin trometamol in treatment of uncomplicated lower urinary tract infections in adult women – an overview. *Infection* 1992;**20**:S310–S312.



**EVALUATION OF THREE-DOSE FOSFOMYCIN
TROMETHAMINE IN THE TREATMENT OF PATIENTS WITH
URINARY TRACT INFECTIONS: AN UNCONTROLLED, OPEN-
LABEL, MULTICENTER STUDY**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004157.R1
Article Type:	Research
Date Submitted by the Author:	12-Nov-2013
Complete List of Authors:	Qiao, Lu-Dong; Beijing Tongren Hospital Capital Medical University, Urology Zheng, Bo; Peking University First Hospital, Institute of Clinical Pharmacology Chen, Shan; Beijing Tongren Hospital Capital Medical University, Urology Yang, Yong; Beijing Cancer Hospital, Urology Zhang, Kai; Peking University First Hospital, Urology Guo, Hong-Feng; Peking University Shougang Hospital (Jieping Wu Urology Center), Urology Yang, Bo; Peking University People's Hospital, Urology Niu, Yuan-Jie; Second Affiliated Hospital of Tianjin Medical University, Urology Wang, Yi; First Affiliated Hospital of Tianjin Medical University, Urology Shi, Ben-Kang; Qilu Hospital of Shandong University, Urology Yang, Wei-Min; Hubei Tongji Hospital, Urology Zhao, Xiao-Kun; Hunan Xiangya Second Hospital, Urology Gao, Xiao-Feng; Shanghai Changhai Hospital, Urology Chen, Ming; Zhongda Hospital affiliated to Southeast University, Urology
Primary Subject Heading:	Urology
Secondary Subject Heading:	Urology
Keywords:	UROLOGY, Urinary tract infections < UROLOGY, Adult urology < UROLOGY

SCHOLARONE™
Manuscripts

**EVALUATION OF THREE-DOSE FOSFOMYCIN TROMETHAMINE IN THE
TREATMENT OF PATIENTS WITH URINARY TRACT INFECTIONS: AN
UNCONTROLLED, OPEN-LABEL, MULTICENTER STUDY**

**Lu-Dong Qiao^{1#}; Bo Zheng^{2#}; Shan Chen^{1*}; Yong Yang³; Kai Zhang⁴; Hong-Feng Guo⁵;
Bo Yang⁶; Yuan-Jie Niu⁷; Yi Wang⁸; Ben-Kang Shi⁹; Wei-Min Yang¹⁰; Xiao-Kun Zhao¹¹;
Xiao-Feng Gao¹²; Ming Chen¹³**

¹Department of Urology. Beijing Tongren Hospital Capital Medical University, Beijing, P. R. China

²Institute of Clinical Pharmacology. Peking University First Hospital, Beijing, P. R. China

³Department of Urology. Beijing Cancer Hospital, Beijing, P. R. China

⁴Department of Urology. Peking University First Hospital, Beijing, P. R. China

⁵Department of Urology. Peking University Shougang Hospital (Jieping Wu Urology Center), Beijing, P. R. China

⁶Department of Urology. Peking University People's Hospital, Beijing, P. R. China

⁷Department of Urology. Second Affiliated Hospital of Tianjin Medical University, Tianjin, P. R. China

⁸Department of Urology. First Affiliated Hospital of China Medical University, Shenyang, P. R. China

⁹Department of Urology, Qilu Hospital of Shandong University, Jinan, P. R. China

¹⁰Department of Urology, Wuhan Hubei Tongji Hospital, Wuhan, P. R. China

¹¹Department of Urology, Hunan Province Xiangya Second Hospital, Changsha, P. R. China

¹²Department of Urology, Shanghai Changhai Hospital, Shanghai, P. R. China

¹³Department of Urology, Zhongda Hospital Southeast University, Nanjing, P. R. China

*Correspondence to: Shan Chen, Department of Urology, Beijing Tongren Hospital Capital

Medical University; Address: No. 1, Dong Jiao Min Xiang, 100730 Beijing, P. R. China;

E-mail: shanchentr001@163.com

#Both authors contributed equally to the study and share first authorship.

Keywords: fosfomycin tromethamine; urinary tract infection; efficacy; safety; China

Word count: 2399

1
2
3
4
5
6 **Abstract:**
7

8
9 **Objective:** To evaluate the clinical and microbiological efficacy and safety of three doses of
10
11
12 3 g fosfomycin tromethamine administered orally to treat lower urinary tract infections.
13

14
15 **Design and participants:** This prospective, uncontrolled, open-label study was conducted in
16
17
18 12 medical centers in China, between January and December 2011. According to the
19
20 diagnosis criteria of Chinese Guidelines on Urological Infections, patients (18–70 years old)
21
22 with acute uncomplicated cystitis, recurrent lower urinary tract infection or complicated
23
24 lower urinary tract infection received three doses of 3 g fosfomycin tromethamine orally, at
25
26 days 1, 3 and 5.
27
28

29
30
31 **Primary and secondary outcome measures:** Efficacy endpoints (clinical efficacy,
32
33 microbiological efficacy and overall efficacy) were evaluated for day 15. Clinical symptoms,
34
35 physical signs, urinalysis, liver and kidney function, patient records and evaluation of adverse
36
37 events (AEs) and serious adverse events (SAEs) up to day 15 were evaluated for analysis of
38
39 safety.
40
41
42

43
44 **Results:** 361 patients were included in the full analysis set (FAS), 356 in the safety analysis
45
46 set (SS) and 335 in the per-protocol set (PPS). In the PPS, the clinical efficacy rates at day 15
47
48 for acute uncomplicated cystitis, recurrent lower urinary tract infection and complicated
49
50 lower urinary tract infection were 94.71% (179/189), 77.22% (61/79), and 62.69% (42/67),
51
52 respectively. Microbiological efficacy rates (day 15) were 97.65% (83/85), 94.44% (34/36)
53
54 and 83.87% (26/31), respectively. The overall efficacy rates (day 15) were 95.29% (81/85),
55
56
57
58
59
60

1
2
3
4 77.78% (28/36) and 64.52% (20/31), respectively. 20/356 (5.6 %) patients reported
5
6 drug-related AEs, the most common being diarrhea. No serious drug-related AEs were
7
8 reported.
9

10
11 **Conclusions:** This fosfomycin tromethamine dosing regimen showed clinical and
12
13 microbiological efficacy with some AEs and good tolerability in patients with acute
14
15 uncomplicated cystitis, recurrent lower urinary tract infection and complicated lower urinary
16
17 tract infection.
18
19
20
21
22
23
24
25

26 **Article summary:**

27 **Article focus:**

- 28
- 29
- 30
- 31
- 32
- 33 • Urinary tract infections (UTIs) are a common clinical infectious disease.
- 34
- 35
- 36 • Increasing drug resistance against other oral antibiotics makes fosfomycin
- 37
- 38 tromethamine a valuable alternative in the treatment of UTIs.
- 39
- 40
- 41
- 42 • The aim of this study was to evaluate the clinical and microbiological efficacy and
- 43
- 44 safety of fosfomycin tromethamine in lower UTI patients from China.
- 45
- 46

47 **Key messages:**

- 48
- 49
- 50
- 51 • Overall, oral administration of three doses of 3 g fosfomycin tromethamine on days 1,
- 52
- 53 3 and 5 showed good clinical and microbiological efficacy in the treatment of acute
- 54
- 55 uncomplicated cystitis, recurrent lower UTI and complicated lower UTI.
- 56
- 57
- 58
- 59
- 60

- The dosage regimen used in this study was associated with a clinically acceptable safety profile, the most frequent adverse event being mild diarrhea, in-line with previous studies. No abnormal laboratory results were recorded.
- Three single 3 g doses of fosfomycin tromethamine taken orally, every other day, were effective and well tolerated. We believe that this dosage regimen can be adopted to treat lower UTIs in clinical practice.

Strengths and limitations of this study:

- To the best of our knowledge, this is the first multicenter study to evaluate fosfomycin tromethamine in the treatment of lower UTIs in China.
- We used the same dosage regimen for the different types of UTI. The dosage may not be sufficient for the complicated lower UTI, but may exceed the required dose for acute uncomplicated cystitis. Further studies using different dosing regimens for the different types of infection are needed.
- Because we aimed to evaluate clinical, microbiological and overall efficacy of fosfomycin tromethamine, the study design did not include a control group.

INTRODUCTION

Urinary tract infections (UTIs) are a common clinical infectious disease. Every year, there are more than 7 million outpatients and about one million patients are hospitalized due to UTIs.[1] Death caused by septic shock due to UTIs ranks third among all lethal infections.[2] In China, UTIs account for 9.39%–50% of all nosocomial infections.[3,4]

In recent years, many resistant strains have emerged as a consequence of the use of broad-spectrum cephalosporins. In particular, strains producing extended-spectrum beta lactamase (ESBL) have created a considerable obstacle in the clinical treatment of UTIs. The fosfomycin derivative fosfomycin tromethamine, a broad-spectrum bactericidal antibiotic inhibiting the synthesis of the bacterial cell wall, has been able to maintain resistance rates amongst *Escherichia coli* as low as 1% worldwide.[5] Available evidence suggests that, even for ESBL-producing *E. coli*, the resistance rate to fosfomycin can be maintained at 3.4%–16.1%.[6,7] The increasing difficulties associated with the growing drug resistance against other oral antibiotics makes fosfomycin even more valuable in the treatment of UTIs. In order to obtain a deeper understanding of its therapeutic effect in domestic patients, we evaluated the clinical and microbiological efficacy and safety in lower UTI patients from 12 research centers in China.

METHODS

Study design and participants

This was a prospective, uncontrolled, open-label, multicenter study approved by the ethics committee of the Beijing Tongren Hospital. Eligible patients were between 18 and 70 years of age and had sought medical help for acute uncomplicated cystitis (AUC), recurrent lower UTI or complicated lower UTI[8] in a urology department of one of 12 medical centers in China (see appendix) from January 2011 to December 2011. All study participants provided informed consent.

The main exclusion criteria were: a history of allergy to fosfomycin; susceptibility results showing resistance to the test drug; fever; grade 3 or 4 cardiac insufficiency; pregnant or lactating women, or women of childbearing age with a positive urine pregnancy test; acute pyelonephritis or acute episode of chronic pyelonephritis; previously diagnosed renal failure; liver disease, with ALT or AST greater than 2 times the upper limit of normal range; white blood cell count less than 2.0×10^9 /L; receipt of other anti-infective drugs within 72 hours before enrollment; patients in the late stages of malignant tumors; long-term use of hormones or immunosuppressants; a history of epilepsy or central nervous system disorders; severe diarrhea; participation in another clinical trial within 3 months prior to enrollment.

Test drug and dosing regimen

1
2
3
4 The test drug was fosfomycin tromethamine powder (3g fosfomycin per bottle), produced by
5
6 Shanxi C&Y Pharmaceutical Co., Ltd., batch number-20100626.
7
8

9
10 Treatment duration was 5 days: on the first day (day 1), a dose of 3g fosfomycin
11
12 tromethamine powder was dissolved with an appropriate amount of water and taken on an
13
14 empty stomach before dinner; two further doses of 3g fosfomycin tromethamine powder were
15
16 taken orally in the evening of days 3 and 5, before bedtime.
17
18
19

20 21 22 23 **Clinical observations**

24
25 Infection signs and symptoms, including frequent, urgent, painful, and difficult urination,
26
27 were noted on days 1, 8, and 15.
28
29

30
31 Blood count, including white blood cells, red blood cells, platelets, neutrophils, lymphocytes,
32
33 eosinophils and hemoglobin, was performed on days 1 and 8. Patients with abnormal levels
34
35 on day 8 were reexamined on day 15.
36
37

38
39 Urinalysis, including urine proteins, red and white blood cells, was performed on days 1, 8,
40
41 and 15.
42
43

44
45 Blood biochemistry, including liver functions (ALT, AST, γ -GT, TBIL, DBIL) and renal
46
47 functions (BUN, Cr), was assessed on days 1 and 8. Patients with abnormal levels on day 8
48
49 were reexamined on day 15.
50
51

52
53 Bacterial cultures were obtained for days 1, 8, and 15, using aseptic techniques to collect
54
55
56
57
58
59
60

1
2
3
4 midstream specimens of urine.
5
6
7
8
9

10 **Evaluation of efficacy and safety**

11
12
13
14 Clinical efficacy, microbiological efficacy, overall efficacy and safety were evaluated on day
15
16 15.

17 18 19 20 Evaluation of clinical efficacy

21
22
23 The clinical effect on the lower UTIs of participants was described using the following 3
24
25 grades: cured (symptoms and signs disappeared completely), improved (symptoms and signs
26
27 improved markedly) and ineffective (symptoms and signs worsened or had no significant
28
29 improvement). Both “cured” and “improved” were considered “effective” results and were
30
31 used to calculate the clinical efficacy rate.
32
33
34

35 36 Evaluation of microbiological efficacy

37
38
39 The microbiological efficacy for each patient with positive urine culture was evaluated from
40
41 day 1. We assessed the microbiological effect using the following 4 grades: eradication (no
42
43 pathogenic bacteria in the urine were present on days 8 and 15), persistence (pathogenic
44
45 bacteria were still present on days 8 and 15 or the patient had a negative culture at day 8, but
46
47 positive for the same bacteria on day 15), replacement (a new pathogenic bacteria was
48
49 detected on days 8 and 15, but the patient had no clinical symptoms and no treatment was
50
51 necessary), and reinfection (a new pathogenic bacteria was detected on days 8 and 15; the
52
53 patient had symptoms and treatment was necessary). Microbiological test results showing
54
55
56
57
58
59
60

1
2
3
4 “eradication”, “replacement” or “reinfection” were considered “effective” results and were
5
6 used to calculate the microbiological efficacy rate.
7
8

9 10 Evaluation of overall efficacy

11
12 Overall efficacy was assessed on patients for whom both clinical and microbiological
13 efficacy data were available by day 15. Four grades were used: excellent (all assessments
14 [clinical symptoms, physical signs, laboratory tests and bacteriological examinations] had
15 returned to normal by day 15), good (the condition improved markedly, but one of the
16 described assessments remained out of the normal range), fair (some improvement was
17 observed after treatment, but two of the described assessments failed to return to normal) and
18 poor (no significant improvement was observed or the assessments worsened). Cases graded
19 as “excellent” or “good” were considered “effective” results and were used to calculate the
20 overall efficacy rate.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Evaluation of safety

37
38 Clinical symptoms, physical signs, urinalysis, liver and kidney function, all patient records
39 and evaluation of adverse events (AEs) and serious adverse events (SAEs) were considered
40 for the safety evaluation. According to their severity, AEs were categorized by patients as
41 follows: “no discomfort”, “mild discomfort”, “moderate discomfort” and “severe discomfort”.
42
43
44
45
46
47
48 The association between AEs and the study drug was assessed by the physician as “definitely
49 related”, “probably related”, “possibly related”, “possibly not related” and “definitely not
50 related”.
51
52
53
54
55
56
57
58
59
60

Statistical methods

The data management software EpiData was used for data entry (Lauritsen JM. EpiData Data Entry, Odense Denmark, EpiData Association, 2000-2008. Available from: <http://www.epidata.dk>). Each case report form was completed by two persons and entry results were compared using SAS software (Version 9.2). The verified data were then entered into a database that was considered as final and correct. For efficacy evaluation, the efficacy rates were calculated as a ratio between the “effective” cases and the total number of patients. For safety analyses, the number of patients with AEs, drug related AEs, and the incidence of AEs were calculated.

The populations included in the analyses were handled as follows: all selected patients who received the study drug were included in the full analysis set (FAS). The per-protocol set (PPS) included the patients from FAS who did not meet the following conditions: (1) inclusion criteria or exclusion criteria violation; (2) use of prohibited concomitant medications; (3) administration of the study drug less than 3 times; (4) failure to undergo the examinations required to determine the clinical effect; (5) poor compliance with the study drug. The PPS population was considered the primary analysis population. All patients who received at least one dose of the study drug and had data available for all safety endpoints were included in the safety analysis set (SAS).

RESULTS

Baseline demographics

361 patients enrolled at 12 centers were included in the FAS. 5 patients did not take the test drugs and were excluded, resulting in 356 patients being included in the SAS. 21 patients were further excluded due to failure to undergo the examinations required to determine the clinical effect, resulting in 335 patients being included in the PPS. Demographic data and infection types for FAS and PPS are shown in Table 1.

Table 1. Demographic characteristics of patients at enrollment

Variables	Parameter	FAS		PPS	
		n	%	n	%
Gender	Male	114	31.58	105	29.08
	Female	247	68.42	230	63.71
Age (years)		49.63 ± 16.64		49.91 ± 16.61	
Height (cm)		163.55 ± 7.12		163.47 ± 7.05	
Weight (kg)		61.36 ± 10.2		61.44 ± 9.81	
Antibiotics*		45	12.53	43	12.84
Hypertension		65	18.01	62	18.51
Diabetes		25	6.93	24	7.16
UTI diagnosis**	AUC	204	56.51	189	56.42
	Recurrent lower UTI	87	24.38	79	23.58
	Complicated lower UTI	69	19.11	67	20.00

Footnote: *use of antibiotics <72 h prior to enrollment; **for 1 patient, the diagnosis was uncertain; FAS = full analysis set; PPS = per-protocol set; AUC = acute uncomplicated cystitis; UTI = urinary tract infection; n = number of patients.

Clinical efficacy

On day 15, the fosfomycin tromethamine treatment showed clinical efficacy in 282/335 patients. Of these, the symptoms and signs of 228/335 (65.07%) patients were graded as “cured”. Clinical efficacy rates for patients of different gender, age, or with different infection types are shown in Table 2.

Table 2. Clinical efficacy at day 15 (per-protocol set)

Variables	n	Effective	Ineffective	Efficacy rate	
		n	n	(%)	
Gender	Male	105	77	28	73.33
	Female	230	205	25	89.13
Age	<50 years	154	137	17	88.96
	≥50 years	181	145	36	80.11
Diagnosis	AUC	189	179	10	94.71
	Recurrent lower UTI	79	61	18	77.22
	Complicated lower UTI	67	42	25	62.69

Footnote: AUC = acute uncomplicated cystitis; UTI = urinary tract infection;

n = number of patients.

Microbiological efficacy

198/356 patients had positive cultures from urine samples collected on day 1, before receiving the first dose of treatment. Causative pathogens and their resistance profiles will be presented elsewhere.

Microbiological efficacy was determined for 152 patients (46/198 patients did not have urine cultures at follow-up visits). 127/152 (83.55%) patients had a microbiological efficacy grade of “eradication”, 9/152(5.92%) patients were graded as “persistence”, 15/152 (9.87%) patients as “replacement” and 1/152(0.66%) patients as “reinfected”. Microbiological outcomes by infection type are shown in Table 3. The percentage of patients with effective treatment in terms of microbiological results was 94.08%. For AUC, recurrent lower UTI and complicated lower UTI, the microbiological efficacy by infection type was 97.65% (83/85), 94.44% (34/36) and 83.87% (26/31), respectively.

Table 3. Microbiological outcomes by infection type (152 cases)

Diagnosis	n	Eradication	Persistence	Replacement/reinfection
		n (%)	n (%)	n (%)
AUC	85	77 (90.59)	2 (2.35)	6 (7.06)
Recurrent lower UTI	36	27 (75.00)	2 (5.56)	7 (19.44)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Complicated lower UTI	31	23 (74.19)	5 (16.13)	3 (9.68)
-----------------------	----	------------	-----------	----------

Footnote: AUC = acute uncomplicated cystitis;

UTI = urinary tract infection; n = number of patients.

Overall efficacy

Overall efficacy was assessed for the 152 patients with available microbiological test results. 106/152 (69.74%) patients were graded as “excellent”, 23/152 (15.13%) patients as “good”, 14/152 (9.21%) patients as “fair” and 9/152 (5.92%) patients as “poor”. Overall efficacy rate by infection type is shown in Table 4.

Table 4. Overall efficacy by infection type (152 cases)

Diagnosis	n	Effective	Ineffective	Efficacy rate
		n	n	(%)
AUC	85	81	4	95.29
Recurrent lower UTI	36	28	8	77.78
Complicated lower UTI	31	20	11	64.52

Footnote: AUC = acute uncomplicated cystitis;

1
2
3
4 UTI = urinary tract infection; n = number of patients.
5
6
7
8
9

10 **Safety evaluation**

11
12
13 AEs were reported in 20/356 (5.6%) patients; and the most frequently reported event was
14 diarrhea (18/356 [5.06%]). 14 patients had mild diarrhea, and 4 had moderate diarrhea. One
15 patient (0.28%) reported mild fatigue and one patient reported mild backache. One patient
16 discontinued the trial due to moderate diarrhea. All other AEs resolved without further
17 treatment. No patients showed abnormal laboratory test results.
18
19
20
21
22
23
24
25
26
27
28
29

30 **DISCUSSION**

31
32
33
34
35
36
37 Fosfomycin tromethamine has been used in clinical practice for many years in Europe, but
38 was rarely used in China until recently. To the best of our knowledge, this is the first
39 multicenter study to evaluate fosfomycin tromethamine in the treatment of lower UTIs in this
40 country. It has been previously observed that one dose of 3 g fosfomycin tromethamine taken
41 orally reaches a peak concentration in the urine of 1053–4415mg/L and the fosfomycin
42 concentration in urine is maintained at levels greater than 128mg/L for 24–48 hours, which is
43 sufficient to suppress a variety of pathogenic bacteria in the urinary tract.[9] In the current
44 study, patients received 3 doses of 3 g fosfomycin tromethamine every other day.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 With bacterial resistance rising worldwide, the European Urology Association adjusted their
5
6 recommendations for the treatment of AUC in the Guidelines on Urological Infections
7
8
9 2010.[10] The initial recommended first-line drugs, such as sulfamethoxazole trimethoprim
10
11 (SMZ TMP) and fluoroquinolones, are now recommended as second choice drugs, while
12
13 fosfomycin tromethamine is now recommended as the preferred treatment. Stein[11] made a
14
15 comprehensive analysis of published randomized controlled clinical studies (Medline
16
17 1970-1997) and unpublished studies submitted to the Food and Drug Administration on
18
19 fosfomycin tromethamine treatment of uncomplicated UTI. The results suggested that a
20
21 single dose of 3g fosfomycin tromethamine, taken orally, is superior in terms of compliance
22
23 and efficacy to conventional therapy (SMZ TMP, nitrofurantoin and fluoroquinolones)
24
25 administered over 3 to 7 days to treat uncomplicated UTIs. In line with this, we obtained
26
27 clinical, microbiological, and overall efficacy rates of 94.71%, 97.65%, and 95.29%,
28
29 respectively, for the treatment of AUC using fosfomycin tromethamine; and 77.22%, 94.44%
30
31 and 77.78%, respectively, for recurrent lower UTI.
32
33
34
35
36
37
38
39

40 Complicated UTIs are associated with conditions such as a structural or functional
41
42 abnormality of the genitourinary tract, or the presence of an underlying disease that interferes
43
44 with host defense mechanisms, increasing the risks of acquiring infection or of failing therapy.
45
46

47 Complicated UTI is caused by a broader spectrum of pathogenic bacteria, and is associated
48
49 with a higher level of drug resistance, than uncomplicated UTI. Domestic research has shown
50
51 that the isolation rate for ESBL-producing *E. coli* is 44% in complicated UTI, with
52
53 susceptibility data showing that ESBL-producing strains have significantly higher resistance
54
55 against commonly used antibiotics than the non-ESBL-producing strains.[12,13] With a
56
57
58
59
60

growing proportion of ESBL-producing strains identified in UTIs, the resistance rate of *E. coli* to commonly used second and third generation cephalosporins has increased to more than 45%.[14] This creates considerable obstacles for effective antimicrobial use in clinical practice. As a direct result, carbapenem has been increasingly used in the empirical treatment of complicated UTI, which has led to an increase in bacterial resistance, an imbalance of commensal flora, and increased risk of fungal infection.[15] Fortunately, unlike resistance against cephalosporins and fluoroquinolones of common UTI pathogens, the resistance rate to fosfomycin has not increased in the recent years.[16] Previous single-center studies have achieved good results with fosfomycin in the treatment of UTIs caused by ESBL-producing bacteria.[17] In line with this, the current study showed clinical, microbiological and overall efficacy rates of 62.69%, 83.87% and 64.52%, respectively, in the treatment of complicated lower UTI.

We observed a low frequency of AEs in the current study. Our findings are in line with an overview of safety and tolerability results from 12 open and double-blind comparative studies,[18] in which 891 female patients received a single 3 g dose of fosfomycin tromethamine. In that study, AEs were reported for 6.1% of the patients, with gastro-intestinal complaints being the most frequent.

One limitation of this study results from the same dosage regimen (3 doses, of 3 g each, of fosfomycin tromethamine taken orally) used for the different types of UTI. The dosage may not be sufficient for the complicated lower UTI, but may exceed the required dosage for simple AUC. Therefore, further in-depth studies will be needed, with different treatment

1
2
3
4 regimens for the different types of infection. Another shortcoming of the study is the lack of a
5
6 control group. This is due to the fact that our primary objective was to evaluate clinical,
7
8 microbiological and overall efficacy of fosfomycin tromethamine, an antibiotic which is
9
10 widely used abroad, but less in China, for the treatment of urinary tract infection.
11
12
13

14 15 16 17 18 **CONCLUSIONS** 19

20
21
22
23
24 The current study suggests that three single 3g doses of fosfomycin tromethamine taken
25
26 orally, every other day, are effective and well tolerated, with a clinically acceptable safety
27
28 profile in the treatment of AUC, recurrent lower UTI or complicated lower UTI. We believe
29
30 that this dosage regimen can be adopted to treat lower UTIs in clinical practice.
31
32
33

34
35
36
37
38 **Acknowledgements:** Authors would like to thank all study participants and the general
39
40 practitioners, study nurses and personnel who contributed to this study. Authors wish to
41
42 acknowledge the support provided by Linyu Li and Jinghan Zhang. Authors also thank
43
44 Juliette Gray and Adriana Rusu (XPE Pharma & Science) for editorial support.
45
46
47
48

49
50 **Contributors:** The work presented here was carried out in collaboration between all authors.
51
52 Shan Chen, Lu-Dong Qiao and Bo Zheng designed the research and defined the research
53
54 theme; Lu-Dong Qiao, Yong Yang, Kai Zhang, Hong-Feng Guo, Bo Yang, Yuan-Jie Niu, Yi
55
56 Wang, Ben-Kang Shi, Wei-Min Yang, Xiao-Kun Zhao, Xiao-Feng Gao and Ming Chen
57
58
59
60

1
2
3
4 performed the research; Shan Chen and Lu-Dong Qiao analyzed the data and interpreted the
5
6 results. All authors contributed to the writing of the paper and have read and approved the
7
8 manuscript.
9

10
11
12 **Funding:** This research received no specific grant from any funding agency in the public,
13
14 commercial or not-for-profit sectors.
15

16
17
18 **Competing interests:** None.
19

20
21 **Data sharing statement:** No additional data are available.
22
23
24
25
26
27
28
29
30

31 Reference list

- 32
33
34
35
36
37
38 1. Foxman B: Epidemiology of urinary tract infections: incidence, morbidity, and economic
39 costs. *Am J Med* 2002;**113**:5S–13S.
40
41
42
43 2. Pinner RW, Teutsch SM, Simonsen L, et al: Trends in infectious disease mortality in the
44 United States. *JAMA* 1996;**275**:189–93.
45
46
47
48 3. Wang JQ, Wu XP, Li YJ, et al: Nosocomial infection point-prevalence survey in three
49 consecutive years. *Chin J Infect Control* 2006;**01**:19–34.
50
51
52
53
54
55 4. Wang JX, Zhu XL, Yang LY: A nosocomial infection point-prevalence survey: results and
56
57
58
59
60

- 1
2
3
4 analysis. *Chinese Journal of Nosocomiology* 2005;**10**:1119–20.
5
6
7 5. Schito GC: Why fosfomycin trometamol as first line therapy for uncomplicated UTI? *Int J*
8
9 *Antimicrob Agents* 2003;**22**:79–83.
10
11
12 6. Qi J, Cheng X: Results analysis of ESBLs-producing *E. coli* in vitro susceptibility to
13
14 fosfomycin. *China Tropical Medicine* 2010;**10**:734–5.
15
16
17 7. Da PN, Rong M, Yong EL: In vitro antimicrobial activity of fosfomycin against
18
19 gram-negative bacilli. *Dalian Medical University* 2010;**32**:577–9.
20
21
22 8. Na YQ, Sun G. Guidelines for diagnosis and treatment of urological diseases in China,
23
24 2009. Beijing: People's Health Publishing House2009:643–4.
25
26
27 9. Patel SS, Balfour JA, Bryson HM: Fosfomycin tromethamine. A review of its antibacterial
28
29 activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral
30
31 treatment for acute uncomplicated lower urinary tract infections. *Drugs* 1997;**53**:637–56.
32
33
34 10. Grabe M, Bjerklund-Johansen TE, Botto H, et al: European Association of Urology,
35
36 Guidelines on Urological Infections, 2010. Available at: <http://www.uroweb.org/>
37
38
39 11. Stein GE: Single-dose treatment of acute cystitis with fosfomycin tromethamine. *Ann*
40
41 *Pharmacother* 1998;**32**:215–9.
42
43
44 12. Qiao LD, Chen S: Analysis of risk factors about ESBLs-producing *E. coli* urinary tract
45
46 infection. *J Hosp Infect* 2011;**21**:247–9.
47
48
49 13. Kong HS, Wang BG: Comparative study of antibiotic resistance in clinical isolates of
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 *Klebsiella pneumoniae* and *Escherichia coli* producing extended-spectrum beta
5
6 lactamases. *J Lab Med* 2000;**23**:23–5.
7
8
9
10 14. Gao L, Xiao YH: 2006 – 2007 Mohnarlin report: Bacterial distribution and resistance in
11
12 urinary tract infections. *Chinese Journal of Antibiotics* 2008;**33**:586–91.
13
14
15 15. Chen H, Liu Y: Relationship between antimicrobial treatment and imbalance of intestinal
16
17 flora in the elders. *Practical Clinical Medicine* 2007;**9**:34–6.
18
19
20
21 16. Pullukcu H, Aydemir S, Tasbakan M, et al: Is there a rise in resistance rates to
22
23 fosfomycin and other commonly used antibiotics in *Escherichia coli*-mediated urinary
24
25 tract infections? A perspective for 2004–2011. *Turk J Med Sci* 2013;**43**:537–41.
26
27
28
29 17. Pullukcu H, Tasbakan M, Sipahi OR, et al: Fosfomycin in the treatment of extended
30
31 spectrum beta-lactamase-producing *Escherichia coli*-related lower urinary tract infections.
32
33 *Int J Antimicrob Agents* 2007;**29**:62–5.
34
35
36
37
38 18. Naber KG: Fosfomycin trometamol in treatment of uncomplicated lower urinary tract
39
40 infections in adult women—an overview. *Infection* 1992;**20**:S310–S312.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**EVALUATION OF THREE-DOSE FOSFOMYCIN TROMETHAMINE IN THE
TREATMENT OF PATIENTS WITH URINARY TRACT INFECTIONS: AN
UNCONTROLLED, OPEN-LABEL, MULTICENTER STUDY**

**Lu-Dong Qiao^{1#}; Bo Zheng^{2#}; Shan Chen^{1*}; Yong Yang³; Kai Zhang⁴; Hong-Feng Guo⁵;
Bo Yang⁶; Yuan-Jie Niu⁷; Yi Wang⁸; Ben-Kang Shi⁹; Wei-Min Yang¹⁰; Xiao-Kun Zhao¹¹;
Xiao-Feng Gao¹²; Ming Chen¹³**

¹Department of Urology. Beijing Tongren Hospital Capital Medical University, Beijing, P. R. China

²Institute of Clinical Pharmacology. Peking University First Hospital, Beijing, P. R. China

³Department of Urology. Beijing Cancer Hospital, Beijing, P. R. China

⁴Department of Urology. Peking University First Hospital, Beijing, P. R. China

⁵Department of Urology. Peking University Shougang Hospital (Jieping Wu Urology Center), Beijing, P. R. China

⁶Department of Urology. Peking University People's Hospital, Beijing, P. R. China

⁷Department of Urology. Second Affiliated Hospital of Tianjin Medical University, Tianjin, P. R. China

⁸Department of Urology. First Affiliated Hospital of China Medical University, Shenyang, P. R. China

⁹Department of Urology. Qilu Hospital of Shandong University, Jinan, P. R. China

¹⁰Department of Urology. Wuhan Hubei Tongji Hospital, Wuhan, P. R. China

¹¹Department of Urology. Hunan Province Xiangya Second Hospital, Changsha, P. R. China

¹²Department of Urology. Shanghai Changhai Hospital, Shanghai, P. R. China

¹³Department of Urology. Zhongda Hospital Southeast University, Nanjing, P. R. China

*Correspondence to: Shan Chen, Department of Urology, Beijing Tongren Hospital Capital

Medical University; Address: No. 1, Dong Jiao Min Xiang, 100730 Beijing, P. R. China;

E-mail: shanchentr001@163.com

#Both authors contributed equally to the study and share first authorship.

Keywords: fosfomicin tromethamine; urinary tract infection; efficacy; safety; China

Word count: 2399

Abstract:

Objective: To evaluate the clinical and microbiological efficacy and safety of three doses of 3 g fosfomycin tromethamine administered orally to treat lower urinary tract infections.

Design and participants: This prospective, uncontrolled, open-label study was conducted in 12 medical centers in China, between January and December 2011. According to the diagnosis criteria of Chinese Guidelines on Urological Infections, patients (18–70 years old) with acute uncomplicated cystitis, recurrent lower urinary tract infection or complicated lower urinary tract infection received three doses of 3 g fosfomycin tromethamine orally, at days 1, 3 and 5.

Primary and secondary outcome measures: Efficacy endpoints (clinical efficacy, microbiological efficacy and overall efficacy) were evaluated for day 15. Clinical symptoms, physical signs, urinalysis, liver and kidney function, patient records and evaluation of adverse events (AEs) and serious adverse events (SAEs) up to day 15 were evaluated for analysis of safety.

Results: 361 patients were included in the full analysis set (FAS), 356 in the safety analysis set (SS) and 335 in the per-protocol set (PPS). In the PPS, the clinical efficacy rates at day 15 for acute uncomplicated cystitis, recurrent lower urinary tract infection and complicated lower urinary tract infection were 94.71% (179/189), 77.22% (61/79), and 62.69% (42/67), respectively. Microbiological efficacy rates (day 15) were 97.65% (83/85), 94.44% (34/36) and 83.87% (26/31), respectively. The overall efficacy rates (day 15) were 95.29% (81/85), 77.78% (28/36) and 64.52% (20/31), respectively. 20/356 (5.6 %) patients reported

1
2
3
4 drug-related AEs, the most common being diarrhea. No serious drug-related AEs were
5
6 reported.

7
8
9
10 **Conclusions:** This fosfomycin tromethamine dosing regimen showed clinical and
11
12 microbiological efficacy with some AEs and good tolerability in patients with acute
13
14 uncomplicated cystitis, recurrent lower urinary tract infection and complicated lower urinary
15
16 tract infection.
17
18

19
20
21
22
23
24 **Article summary:**

25
26
27 **Article focus:**

- 28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
- Urinary tract infections (UTIs) are a common clinical infectious disease.
 - Increasing drug resistance against other oral antibiotics makes fosfomycin tromethamine a valuable alternative in the treatment of UTIs.
 - The aim of this study was to evaluate the clinical and microbiological efficacy and safety of fosfomycin tromethamine in lower UTI patients from China.

45
46
47 **Key messages:**

- 48
49
50
51
52
53
54
55
56
57
58
59
60
- Overall, oral administration of three doses of 3 g fosfomycin tromethamine on days 1, 3 and 5 showed good clinical and microbiological efficacy in the treatment of acute uncomplicated cystitis, recurrent lower UTI and complicated lower UTI.
 - The dosage regimen used in this study was associated with a clinically acceptable

1
2
3
4 safety profile, the most frequent adverse event being mild diarrhea, in-line with
5
6 previous studies. No abnormal laboratory results were recorded.
7
8

- 9
10
11
12
13
14
15
16
17
- Three single 3 g doses of fosfomycin tromethamine taken orally, every other day, were effective and well tolerated. We believe that this dosage regimen can be adopted to treat lower UTIs in clinical practice.

18
19
20

Strengths and limitations of this study:

- 21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- To the best of our knowledge, this is the first multicenter study to evaluate fosfomycin tromethamine in the treatment of lower UTIs in China.
 - We used the same dosage regimen for the different types of UTI. The dosage may not be sufficient for the complicated lower UTI, but may exceed the required dose for acute uncomplicated cystitis. Further studies using different dosing regimens for the different types of infection are needed.
 - Because we aimed to evaluate clinical, microbiological and overall efficacy of fosfomycin tromethamine, the study design did not include a control group.

INTRODUCTION

Urinary tract infections (UTIs) are a common clinical infectious disease. Every year, there are more than 7 million outpatients and about one million patients are hospitalized due to UTIs.[1] Death caused by septic shock due to UTIs ranks third among all lethal infections.[2] In China, UTIs account for 9.39%–50% of all nosocomial infections.[3,4]

In recent years, many resistant strains have emerged as a consequence of the use of broad-spectrum cephalosporins. In particular, strains producing extended-spectrum beta lactamase (ESBL) have created a considerable obstacle in the clinical treatment of UTIs. The fosfomycin derivative fosfomycin tromethamine, a broad-spectrum bactericidal antibiotic inhibiting the synthesis of the bacterial cell wall, has been able to maintain resistance rates amongst *Escherichia coli* as low as 1% worldwide.[5] Available evidence suggests that, even for ESBL-producing *E. coli*, the resistance rate to fosfomycin can be maintained at 3.4%–16.1%.[6,7] The increasing difficulties associated with the growing drug resistance against other oral antibiotics makes fosfomycin even more valuable in the treatment of UTIs. In order to obtain a deeper understanding of its therapeutic effect in domestic patients, we evaluated the clinical and microbiological efficacy and safety in lower UTI patients from 12 research centers in China.

METHODS

Study design and participants

This was a prospective, uncontrolled, open-label, multicenter study approved by the ethics committee of the Beijing Tongren Hospital. Eligible patients were between 18 and 70 years of age and had sought medical help for acute uncomplicated cystitis (AUC), recurrent lower UTI or complicated lower UTI[8] in a urology department of one of 12 medical centers in China (see appendix) from January 2011 to December 2011. All study participants provided informed consent.

The main exclusion criteria were: a history of allergy to fosfomycin; susceptibility results showing resistance to the test drug; fever; grade 3 or 4 cardiac insufficiency; pregnant or lactating women, or women of childbearing age with a positive urine pregnancy test; acute pyelonephritis or acute episode of chronic pyelonephritis; previously diagnosed renal failure; liver disease, with ALT or AST greater than 2 times the upper limit of normal range; white blood cell count less than 2.0×10^9 /L; receipt of other anti-infective drugs within 72 hours before enrollment; patients in the late stages of malignant tumors; long-term use of hormones or immunosuppressants; a history of epilepsy or central nervous system disorders; severe diarrhea; participation in another clinical trial within 3 months prior to enrollment.

Test drug and dosing regimen

The test drug was fosfomycin tromethamine powder (3g fosfomycin per bottle), produced by

1
2
3
4 Shanxi C&Y Pharmaceutical Co., Ltd., batch number-20100626.
5
6

7 Treatment duration was 5 days: on the first day (day 1), a dose of 3g fosfomycin
8
9 tromethamine powder was dissolved with an appropriate amount of water and taken on an
10
11 empty stomach before dinner; two further doses of 3g fosfomycin tromethamine powder were
12
13 taken orally in the evening of days 3 and 5, before bedtime.
14
15
16
17
18
19
20

21 **Clinical observations**

22
23
24 Infection signs and symptoms, including frequent, urgent, painful, and difficult urination,
25
26 were noted on days 1, 8, and 15.
27
28
29

30 Blood count, including white blood cells, red blood cells, platelets, neutrophils, lymphocytes,
31
32 eosinophils and hemoglobin, was performed on days 1 and 8. Patients with abnormal levels
33
34 on day 8 were reexamined on day 15.
35
36
37

38 Urinalysis, including urine proteins, red and white blood cells, was performed on days 1, 8,
39
40 and 15.
41
42
43

44 Blood biochemistry, including liver functions (ALT, AST, γ -GT, TBIL, DBIL) and renal
45
46 functions (BUN, Cr), was assessed on days 1 and 8. Patients with abnormal levels on day 8
47
48 were reexamined on day 15.
49
50
51

52 Bacterial cultures were obtained for days 1, 8, and 15, using aseptic techniques to collect
53
54 midstream specimens of urine.
55
56
57
58
59
60

Evaluation of efficacy and safety

Clinical efficacy, microbiological efficacy, overall efficacy and safety were evaluated on day 15.

Evaluation of clinical efficacy

The clinical effect on the lower UTIs of participants was described using the following 3 grades: cured (symptoms and signs disappeared completely), improved (symptoms and signs improved markedly) and ineffective (symptoms and signs worsened or had no significant improvement). Both “cured” and “improved” were considered “effective” results and were used to calculate the clinical efficacy rate.

Evaluation of microbiological efficacy

The microbiological efficacy for each patient with positive urine culture was evaluated from day 1. We assessed the microbiological effect using the following 4 grades: eradication (no pathogenic bacteria in the urine were present on days 8 and 15), persistence (pathogenic bacteria were still present on days 8 and 15 or the patient had a negative culture at day 8, but positive for the same bacteria on day 15), replacement (a new pathogenic bacteria was detected on days 8 and 15, but the patient had no clinical symptoms and no treatment was necessary), and reinfection (a new pathogenic bacteria was detected on days 8 and 15; the patient had symptoms and treatment was necessary). Microbiological test results showing “eradication”, “replacement” or “reinfection” were considered “effective” results and were

1
2
3
4 used to calculate the microbiological efficacy rate.
5
6

7 Evaluation of overall efficacy

8
9

10 Overall efficacy was assessed on patients for whom both clinical and microbiological
11 efficacy data were available by day 15. Four grades were used: excellent (all assessments
12 [clinical symptoms, physical signs, laboratory tests and bacteriological examinations] had
13 returned to normal by day 15), good (the condition improved markedly, but one of the
14 described assessments remained out of the normal range), fair (some improvement was
15 observed after treatment, but two of the described assessments failed to return to normal) and
16 poor (no significant improvement was observed or the assessments worsened). Cases graded
17 as “excellent” or “good” were considered “effective” results and were used to calculate the
18 overall efficacy rate.
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Evaluation of safety

34
35
36

37 Clinical symptoms, physical signs, urinalysis, liver and kidney function, all patient records
38 and evaluation of adverse events (AEs) and serious adverse events (SAEs) were considered
39 for the safety evaluation. According to their severity, AEs were categorized by patients as
40 follows: “no discomfort”, “mild discomfort”, “moderate discomfort” and “severe discomfort”.
41
42
43
44
45
46
47 The association between AEs and the study drug was assessed by the physician as “definitely
48 related”, “probably related”, “possibly related”, “possibly not related” and “definitely not
49 related”.
50
51
52
53
54
55
56
57
58
59
60

Statistical methods

The data management software EpiData was used for data entry (Lauritsen JM. EpiData Data Entry, Odense Denmark, EpiData Association, 2000-2008. Available from: <http://www.epidata.dk>). Each case report form was completed by two persons and entry results were compared using SAS software (Version 9.2). The verified data were then entered into a database that was considered as final and correct. For efficacy evaluation, the efficacy rates were calculated as a ratio between the “effective” cases and the total number of patients. For safety analyses, the number of patients with AEs, drug related AEs, and the incidence of AEs were calculated.

The populations included in the analyses were handled as follows: all selected patients who received the study drug were included in the full analysis set (FAS). The per-protocol set (PPS) included the patients from FAS who did not meet the following conditions: (1) inclusion criteria or exclusion criteria violation; (2) use of prohibited concomitant medications; (3) administration of the study drug less than 3 times; (4) failure to undergo the examinations required to determine the clinical effect; (5) poor compliance with the study drug. The PPS population was considered the primary analysis population. All patients who received at least one dose of the study drug and had data available for all safety endpoints were included in the safety analysis set (SAS).

RESULTS

Baseline demographics

361 patients enrolled at 12 centers were included in the FAS. 5 patients did not take the test drugs and were excluded, resulting in 356 patients being included in the SAS. 21 patients were further excluded due to failure to undergo the examinations required to determine the clinical effect, resulting in 335 patients being included in the PPS. Demographic data and infection types for FAS and PPS are shown in Table 1.

Table 1. Demographic characteristics of patients at enrollment

Variables	Parameter	FAS		PPS	
		n	%	n	%
Gender	Male	114	31.58	105	29.08
	Female	247	68.42	230	63.71
Age (years)		49.63 ± 16.64		49.91 ± 16.61	
Height (cm)		163.55 ± 7.12		163.47 ± 7.05	
Weight (kg)		61.36 ± 10.2		61.44 ± 9.81	
Antibiotics*		45	12.53	43	12.84
Hypertension		65	18.01	62	18.51
Diabetes		25	6.93	24	7.16
UTI diagnosis**	AUC	204	56.51	189	56.42
	Recurrent lower UTI	87	24.38	79	23.58
	Complicated lower UTI	69	19.11	67	20.00

Footnote: *use of antibiotics <72 h prior to enrollment; **for 1 patient, the diagnosis was uncertain; FAS = full analysis set; PPS = per-protocol set; AUC = acute uncomplicated cystitis; UTI = urinary tract infection; n = number of patients.

Clinical efficacy

On day 15, the fosfomycin tromethamine treatment showed clinical efficacy in 282/335 patients. Of these, the symptoms and signs of 228/335 (65.07%) patients were graded as “cured”. Clinical efficacy rates for patients of different gender, age, or with different infection types are shown in Table 2.

Table 2. Clinical efficacy at day 15 (per-protocol set)

Variables	n	Effective	Ineffective	Efficacy rate	
		n	n	(%)	
Gender	Male	105	77	28	73.33
	Female	230	205	25	89.13
Age	<50 years	154	137	17	88.96
	≥50 years	181	145	36	80.11
Diagnosis	AUC	189	179	10	94.71
	Recurrent lower UTI	79	61	18	77.22
	Complicated lower UTI	67	42	25	62.69

Footnote: AUC = acute uncomplicated cystitis; UTI = urinary tract infection;

n = number of patients.

Microbiological efficacy

198/356 patients had positive cultures from urine samples collected on day 1, before receiving the first dose of treatment. Causative pathogens and their resistance profiles will be presented elsewhere.

Microbiological efficacy was determined for 152 patients (46/198 patients did not have urine cultures at follow-up visits). 127/152 (83.55%) patients had a microbiological efficacy grade of “eradication”, 9/152(5.92%) patients were graded as “persistence”, 15/152 (9.87%) patients as “replacement” and 1/152(0.66%) patients as “reinfected”. Microbiological outcomes by infection type are shown in Table 3. The percentage of patients with effective treatment in terms of microbiological results was 94.08%. For AUC, recurrent lower UTI and complicated lower UTI, the microbiological efficacy by infection type was 97.65% (83/85), 94.44% (34/36) and 83.87% (26/31), respectively.

Table 3. Microbiological outcomes by infection type (152 cases)

Diagnosis	n	Eradication	Persistence	Replacement/reinfection
		n (%)	n (%)	n (%)
AUC	85	77 (90.59)	2 (2.35)	6 (7.06)
Recurrent lower UTI	36	27 (75.00)	2 (5.56)	7 (19.44)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Complicated lower UTI	31	23 (74.19)	5 (16.13)	3 (9.68)
-----------------------	----	------------	-----------	----------

Footnote: AUC = acute uncomplicated cystitis;

UTI = urinary tract infection; n = number of patients.

Overall efficacy

Overall efficacy was assessed for the 152 patients with available microbiological test results. 106/152 (69.74%) patients were graded as “excellent”, 23/152 (15.13%) patients as “good”, 14/152 (9.21%) patients as “fair” and 9/152 (5.92%) patients as “poor”. Overall efficacy rate by infection type is shown in Table 4.

Table 4. Overall efficacy by infection type (152 cases)

Diagnosis	n	Effective	Ineffective	Efficacy rate
		n	n	(%)
AUC	85	81	4	95.29
Recurrent lower UTI	36	28	8	77.78
Complicated lower UTI	31	20	11	64.52

Footnote: AUC = acute uncomplicated cystitis;

UTI = urinary tract infection; n = number of patients.

Safety evaluation

AEs were reported in 20/356 (5.6%) patients; and the most frequently reported event was diarrhea (18/356 [5.06%]). 14 patients had mild diarrhea, and 4 had moderate diarrhea. One patient (0.28%) reported mild fatigue and one patient reported mild backache. One patient discontinued the trial due to moderate diarrhea. All other AEs resolved without further treatment. No patients showed abnormal laboratory test results.

DISCUSSION

Fosfomycin tromethamine has been used in clinical practice for many years in Europe, but was rarely used in China until recently. To the best of our knowledge, this is the first multicenter study to evaluate fosfomycin tromethamine in the treatment of lower UTIs in this country. It has been previously observed that one dose of 3 g fosfomycin tromethamine taken orally reaches a peak concentration in the urine of 1053–4415mg/L and the fosfomycin concentration in urine is maintained at levels greater than 128mg/L for 24–48 hours, which is sufficient to suppress a variety of pathogenic bacteria in the urinary tract.[9] In the current study, patients received 3 doses of 3 g fosfomycin tromethamine every other day.

1
2
3
4 With bacterial resistance rising worldwide, the European Urology Association adjusted their
5
6 recommendations for the treatment of AUC in the Guidelines on Urological Infections
7
8 2010.[10] The initial recommended first-line drugs, such as sulfamethoxazole trimethoprim
9
10 (SMZ TMP) and fluoroquinolones, are now recommended as second choice drugs, while
11
12 fosfomycin tromethamine is now recommended as the preferred treatment. Stein[11] made a
13
14 comprehensive analysis of published randomized controlled clinical studies (Medline
15
16 1970-1997) and unpublished studies submitted to the Food and Drug Administration on
17
18 fosfomycin tromethamine treatment of uncomplicated UTI. The results suggested that a
19
20 single dose of 3g fosfomycin tromethamine, taken orally, is superior in terms of compliance
21
22 and efficacy to conventional therapy (SMZ TMP, nitrofurantoin and fluoroquinolones)
23
24 administered over 3 to 7 days to treat uncomplicated UTIs. In line with this, we obtained
25
26 clinical, microbiological, and overall efficacy rates of 94.71%, 97.65%, and 95.29%,
27
28 respectively, for the treatment of AUC using fosfomycin tromethamine; and 77.22%, 94.44%
29
30 and 77.78%, respectively, for recurrent lower UTI.

31
32
33
34
35
36
37
38
39 Complicated UTIs are associated with conditions such as a structural or functional
40
41 abnormality of the genitourinary tract, or the presence of an underlying disease that interferes
42
43 with host defense mechanisms, increasing the risks of acquiring infection or of failing therapy.
44
45
46
47 Complicated UTI is caused by a broader spectrum of pathogenic bacteria, and is associated
48
49 with a higher level of drug resistance, than uncomplicated UTI. Domestic research has shown
50
51 that the isolation rate for ESBL-producing *E. coli* is 44% in complicated UTI, with
52
53 susceptibility data showing that ESBL-producing strains have significantly higher resistance
54
55 against commonly used antibiotics than the non-ESBL-producing strains.[12,13] With a
56
57
58
59
60

growing proportion of ESBL-producing strains identified in UTIs, the resistance rate of *E. coli* to commonly used second and third generation cephalosporins has increased to more than 45%.[14] This creates considerable obstacles for effective antimicrobial use in clinical practice. As a direct result, carbapenem has been increasingly used in the empirical treatment of complicated UTI, which has led to an increase in bacterial resistance, an imbalance of commensal flora, and increased risk of fungal infection.[15] Fortunately, unlike resistance against cephalosporins and fluoroquinolones of common UTI pathogens, the resistance rate to fosfomycin has not increased in the recent years.[16] Previous single-center studies have achieved good results with fosfomycin in the treatment of UTIs caused by ESBL-producing bacteria.[17] In line with this, the current study showed clinical, microbiological and overall efficacy rates of 62.69%, 83.87% and 64.52%, respectively, in the treatment of complicated lower UTI.

We observed a low frequency of AEs in the current study. Our findings are in line with an overview of safety and tolerability results from 12 open and double-blind comparative studies,[18] in which 891 female patients received a single 3 g dose of fosfomycin tromethamine. In that study, AEs were reported for 6.1% of the patients, with gastro-intestinal complaints being the most frequent.

One limitation of this study results from the same dosage regimen (3 doses, of 3 g each, of fosfomycin tromethamine taken orally) used for the different types of UTI. The dosage may not be sufficient for the complicated lower UTI, but may exceed the required dosage for simple AUC. Therefore, further in-depth studies will be needed, with different treatment

1
2
3
4 regimens for the different types of infection. Another shortcoming of the study is the lack of a
5
6 control group. This is due to the fact that our primary objective was to evaluate clinical,
7
8 microbiological and overall efficacy of fosfomycin tromethamine, an antibiotic which is
9
10 widely used abroad, but less in China, for the treatment of urinary tract infection.
11
12

13 14 15 16 17 18 **CONCLUSIONS** 19

20
21
22
23
24 The current study suggests that three single 3g doses of fosfomycin tromethamine taken
25
26 orally, every other day, are effective and well tolerated, with a clinically acceptable safety
27
28 profile in the treatment of AUC, recurrent lower UTI or complicated lower UTI. We believe
29
30 that this dosage regimen can be adopted to treat lower UTIs in clinical practice.
31
32
33
34
35
36
37
38

39 **Acknowledgements:** Authors would like to thank all study participants and the general
40
41 practitioners, study nurses and personnel who contributed to this study. Authors wish to
42
43 acknowledge the support provided by Linyu Li and Jinghan Zhang. Authors also thank
44
45 Juliette Gray and Adriana Rusu (XPE Pharma & Science) for editorial support.
46
47
48

49 **Contributors:** The work presented here was carried out in collaboration between all authors.
50
51 Shan Chen, Lu-Dong Qiao and Bo Zheng designed the research and defined the research
52
53 theme; Lu-Dong Qiao, Yong Yang, Kai Zhang, Hong-Feng Guo, Bo Yang, Yuan-Jie Niu, Yi
54
55 Wang, Ben-Kang Shi, Wei-Min Yang, Xiao-Kun Zhao, Xiao-Feng Gao and Ming Chen
56
57
58
59
60

1
2
3
4 performed the research; Shan Chen and Lu-Dong Qiao analyzed the data and interpreted the
5
6 results. All authors contributed to the writing of the paper and have read and approved the
7
8 manuscript.
9

10
11 **Funding:** This research received no specific grant from any funding agency in the public,
12
13 commercial or not-for-profit sectors.
14

15
16
17 **Competing interests:** None.
18

19
20
21 **Data sharing statement:** No additional data are available.
22
23

24 25 26 27 28 29 30 31 **Reference list** 32 33

- 34
35
36
37
38 1. Foxman B: Epidemiology of urinary tract infections: incidence, morbidity, and economic
39 costs. *Am J Med* 2002;**113**:5S–13S.
40
41
42
43 2. Pinner RW, Teutsch SM, Simonsen L, et al: Trends in infectious disease mortality in the
44 United States. *JAMA* 1996;**275**:189–93.
45
46
47
48 3. Wang JQ, Wu XP, Li YJ, et al: Nosocomial infection point-prevalence survey in three
49 consecutive years. *Chin J Infect Control* 2006;**01**:19–34.
50
51
52
53 4. Wang JX, Zhu XL, Yang LY: A nosocomial infection point-prevalence survey: results and
54
55
56
57
58
59
60

- 1
2
3
4 analysis. *Chinese Journal of Nosocomiology* 2005;**10**:1119–20.
5
6
7 5. Schito GC: Why fosfomycin trometamol as first line therapy for uncomplicated UTI? *Int J*
8
9 *Antimicrob Agents* 2003;**22**:79–83.
10
11
12 6. Qi J, Cheng X: Results analysis of ESBLs-producing *E. coli* in vitro susceptibility to
13
14 fosfomycin. *China Tropical Medicine* 2010;**10**:734–5.
15
16
17 7. Da PN, Rong M, Yong EL: In vitro antimicrobial activity of fosfomycin against
18
19 gram-negative bacilli. *Dalian Medical University* 2010;**32**:577–9.
20
21
22 8. Na YQ, Sun G. Guidelines for diagnosis and treatment of urological diseases in China,
23
24 2009. Beijing: People's Health Publishing House2009:643–4.
25
26
27 9. Patel SS, Balfour JA, Bryson HM: Fosfomycin tromethamine. A review of its antibacterial
28
29 activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral
30
31 treatment for acute uncomplicated lower urinary tract infections. *Drugs* 1997;**53**:637–56.
32
33
34 10. Grabe M, Bjerklund-Johansen TE, Botto H, et al: European Association of Urology,
35
36 Guidelines on Urological Infections, 2010. Available at: <http://www.uroweb.org/>
37
38
39 11. Stein GE: Single-dose treatment of acute cystitis with fosfomycin tromethamine. *Ann*
40
41 *Pharmacother* 1998;**32**:215–9.
42
43
44 12. Qiao LD, Chen S: Analysis of risk factors about ESBLs-producing *E. coli* urinary tract
45
46 infection. *J Hosp Infect* 2011;**21**:247–9.
47
48
49 13. Kong HS, Wang BG: Comparative study of antibiotic resistance in clinical isolates of
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 *Klebsiella pneumoniae* and *Escherichia coli* producing extended-spectrum beta
5
6 lactamases. *J Lab Med* 2000;**23**:23–5.
7
8
9
10 14. Gao L, Xiao YH: 2006 – 2007 Mohnarlin report: Bacterial distribution and resistance in
11
12 urinary tract infections. *Chinese Journal of Antibiotics* 2008;**33**:586–91.
13
14
15 15. Chen H, Liu Y: Relationship between antimicrobial treatment and imbalance of intestinal
16
17 flora in the elders. *Practical Clinical Medicine* 2007;**9**:34–6.
18
19
20
21 16. Pullukcu H, Aydemir S, Tasbakan M, et al: Is there a rise in resistance rates to
22
23 fosfomycin and other commonly used antibiotics in *Escherichia coli*-mediated urinary
24
25 tract infections? A perspective for 2004–2011. *Turk J Med Sci* 2013;**43**:537–41.
26
27
28
29
30 17. Pullukcu H, Tasbakan M, Sipahi OR, et al: Fosfomycin in the treatment of extended
31
32 spectrum beta-lactamase-producing *Escherichia coli*-related lower urinary tract infections.
33
34 *Int J Antimicrob Agents* 2007;**29**:62–5.
35
36
37
38 18. Naber KG: Fosfomycin trometamol in treatment of uncomplicated lower urinary tract
39
40 infections in adult women—an overview. *Infection* 1992;**20**:S310–S312.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60